PLIANT THERAPEUTICS, INC. — Director's Dealing 2021

Mar 20, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PLIANT THERAPEUTICS, INC. (PLRX)
CIK: 0001746473
Period of Report: 2021-03-18

Reporting Person: Lefebvre Eric (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-18	Common Stock	S	11365	$39.3777	Disposed	150715	Direct
2021-03-18	Common Stock	S	1135	$39.7799	Disposed	149580	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2020.

F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $38.72 to $39.70, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.72 to $39.84, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.